See more : Virgin Money UK PLC (CBBYF) Income Statement Analysis – Financial Results
Complete financial analysis of DiaMedica Therapeutics Inc. (DMAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DiaMedica Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ichigo Hotel REIT Investment Corporation (3463.T) Income Statement Analysis – Financial Results
- Diatreme Resources Limited (DRX.AX) Income Statement Analysis – Financial Results
- JSW Infrastructure Limited (JSWINFRA.BO) Income Statement Analysis – Financial Results
- Ferrellgas Partners, L.P. (FGPRB) Income Statement Analysis – Financial Results
- Nordex SE (NRDXF) Income Statement Analysis – Financial Results
DiaMedica Therapeutics Inc. (DMAC)
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Cost of Revenue | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 0.00 | 4.00K | 2.21K | 4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.00K | -25.00K | -24.00K | -21.00K | -21.00K | 500.00K | -4.00K | -2.21K | -4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 13.11M | 7.84M | 8.77M | 8.31M | 7.90M | 4.52M | 3.21M | 1.76M | 886.07K | 3.71M | 3.78M | 5.21M | 2.33M | 803.98K | 1.37M | 1.04M | 1.07M | 617.26K | 22.75K | 462.00K |
| General & Administrative | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 1.38M | 192.37K | 177.78K | 168.91K |
| Other Expenses | 0.00 | 353.00K | 82.00K | -205.00K | -856.00K | -68.00K | 6.00K | 221.90K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.58K | -4.89K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Cost & Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.73K | 1.74K | 10.54K | 14.73K | 41.03K | 51.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.38K | 43.96K | 0.00 | 7.73K | 2.72K | 12.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.60K | 36.59K |
| Depreciation & Amortization | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 15.00K | 4.00K | 2.21K | 4.11K | 2.47K | 1.11M | 2.37M | 2.30M | 1.67M | 30.20K | 26.74K | 18.35K | 3.32K | 28.15K | 6.41K |
| EBITDA | -19.31M | -13.98M | -13.62M | -12.24M | -10.60M | -5.64M | -4.26M | -2.15M | -1.50M | -5.01M | -6.51M | -7.70M | -4.51M | -3.32M | -2.27M | -2.34M | -2.29M | -783.89K | -190.26K | -630.30K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.62% | -3,045.78% | -680.92% | -1,762.12% |
| Operating Income | -21.27M | -14.00M | -13.65M | -12.70M | -11.59M | -6.76M | -4.52M | -2.48M | -1.31M | -4.83M | -7.43M | -10.11M | -6.71M | -3.84M | -2.40M | -1.69M | -2.31M | -787.21K | -203.01K | -603.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,352.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,438.05% | -3,058.67% | -790.56% | -1,781.04% |
| Total Other Income/Expenses | 1.93M | 353.00K | 82.00K | 434.00K | 975.00K | 747.00K | 259.00K | 280.63K | -104.38K | -185.41K | -230.99K | 37.57K | -174.26K | -422.84K | 101.28K | -168.32K | 57.19K | -12.38K | 10.28K | 66.55K |
| Income Before Tax | -19.34M | -13.65M | -13.56M | -12.27M | -10.62M | -5.65M | -4.26M | -2.20M | -1.43M | -4.78M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.31M | 0.00 | -192.73K | -570.16K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,130.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,440.21% | 0.00% | -750.53% | -1,682.83% |
| Income Tax Expense | 43.00K | 28.00K | 28.00K | 27.00K | 31.00K | 80.00K | -9.00K | 22.31K | 12.45K | 42.28K | 7.73K | 2.72K | 12.57K | 499.08K | 41.69K | 163.43K | 20.20K | -9.19K | 17.87K | 69.86K |
| Net Income | -19.38M | -13.68M | -13.59M | -12.29M | -10.65M | -5.73M | -4.26M | -2.22M | -1.44M | -4.82M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.33M | -778.02K | -210.60K | -640.02K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,452.78% | -3,022.96% | -820.13% | -1,889.02% |
| EPS | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| EPS Diluted | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| Weighted Avg Shares Out | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
| Weighted Avg Shares Out (Dil) | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
DiaMedica Therapeutics Announces $11.8 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors....
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia....
DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer Scott Kellen - CFO & Company Secretary Conference Call...
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close...
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199...
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts'...
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.
Source: https://incomestatements.info
Category: Stock Reports